Research programme: SSAO/VAP-1 protein inhibitors - Pharmaxis

Drug Profile

Research programme: SSAO/VAP-1 protein inhibitors - Pharmaxis

Alternative Names: PXS4159; PXS4206

Latest Information Update: 30 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmaxis
  • Class Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 17 May 2015 Boehringer Ingelheim acquires SSAO/VAP-1 protein inhbitors from Pharmaxis
  • 12 Mar 2015 Boehringer Ingelheim enters into an Option and Asset Purchase Agreement with Pharmaxis for SSAO/VAP‐1 inhibitor molecules
  • 22 Jan 2015 Discontinued - Preclinical for Asthma in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top